Simultaneous 18F-fluciclovine Positron Emission Tomography and Magnetic Resonance Spectroscopic Imaging of Prostate Cancer

Esmaeili, Morteza; Tayari, Nassim; Scheenen, Tom W. J.; Elschot, Mattijs; Sandsmark, Elise; Bertilsson, Helena; Heerschap, Arend; Selnæs, Kirsten Margrete; Bathen, Tone Frost

doi:10.3389/fonc.2018.00516

Cited by 5 publications

(5 citation statements)

References 76 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reasons for exclusion were no systematic sector-based histopathology [13][14][15][16][17][18][19][20][21][22] or inappropriate study design and/or not within the scope of the review. [23][24][25]…”

Section: Evidence Synthesis Search Resultsmentioning

confidence: 99%

18F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard

et al. 2021

View full text Add to dashboard Cite

BACKGROUND Prostate cancer is the most common cancer in men, and has the second-highest mortality among male malignant carcinomas. 1 At initial diagnosis, the extent and spread of the cancer are key factors in deciding the appropriate treatment. For localized disease, the main treatment modalities are radical prostatectomy, external beam radiotherapy, or brachytherapy. About one-third of patients develop recurrence after primary definitive treatment. 2 Localization of recurrent disease is critical to the subsequent therapeutic strategy and prognosis because focal salvage treatment options are emerging. 3,4 In the past, the role of PET for prostate cancer imaging has been limited. However, in recent years, several new PET tracers have emerged that offer improved diagnostic performance for detecting localized disease and metastases at initial diagnosis and localize disease recurrence. 5 One of these PET tracers is trans-1-amino-3-18 Ffluorocyclobutanecarboxylic acid (anti-18 F-FACBC, 18 F-fluciclovine). 18 F-fluciclovine is a radiolabeled amino acid analogue that exploits the increased demand of amino acids in tumor tissue for prostate cancer imaging 6 (Fig. 1). Long half-life and limited urinary excretion are also desirable features of 18 F-fluciclovine. 7 At present,

show abstract

Section: Evidence Synthesis Search Resultsmentioning

confidence: 99%

18F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In this retrospective multicenter study, we used data from a cohort of patients ( N = 92) recruited from June 2010 to August 2015 in a clinical trial aiming to localize PCa with a multiparametric MR approach (PCa‐MAP; ClinicalTrials.gov Identifier NCT01138527) 22,31 . This dataset was supplemented with 14 high‐risk patients who had more aggressive tumors and were at a high risk of metastasized disease, examined by a combined 18 F‐fluciclovine positron emission tomography (PET)/MRI including MRSI protocol (ClinicalTrials.gov; identifier NCT02076503) 32 . All patients ( N = 106) had biopsy‐proven PCa and no history of therapy to the prostate, other pelvic organs, or androgen‐deprivation therapy.…”

Section: Methodsmentioning

confidence: 99%

“…22,31 This dataset was supplemented with 14 high-risk patients who had more aggressive tumors and were at a high risk of metastasized disease, examined by a combined 18 F-fluciclovine positron emission tomography (PET)/MRI including MRSI protocol (ClinicalTrials.gov; identifier NCT02076503). 32 All patients (N = 106) had biopsy-proven PCa and no history of therapy to the prostate, other pelvic organs, or androgen-deprivation therapy. Patients from the trial (N = 92) underwent a preoperative mpMRI examination and a scheduled radical prostatectomy with whole-mount or quartile-divided histopathology of the resected prostate.…”

Section: Patient Populationmentioning

confidence: 99%

“…In this work, we applied the multivariate curve resolution alternating least squares (MCR-ALS) method 28 to analyze three-dimensional (3D) 1 H-MRSI data of the prostate from PCa patients, acquired from multiple institutions. 31,32 This method produces the relative intensities of a selected number of components reflecting spectral profiles obtained from a large training set of patients, generating an interpretable model. 33 The resulting components were assigned to certain tissue types and subsequently validated using data that were not included in the training set and compared with histopathology reports and previously identified regions of interest as the reference standard.…”

Section: Introductionmentioning

confidence: 99%

“…In this work, we applied the multivariate curve resolution alternating least squares (MCR‐ALS) method 28 to analyze three‐dimensional (3D) 1 H‐MRSI data of the prostate from PCa patients, acquired from multiple institutions 31,32 . This method produces the relative intensities of a selected number of components reflecting spectral profiles obtained from a large training set of patients, generating an interpretable model 33 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A multivariate curve resolution analysis of multicenter proton spectroscopic imaging of the prostate for cancer localization and assessment of aggressiveness

Stamatelatou,

Bertinetto,

Jansen

et al. 2023

NMR in Biomedicine

Self Cite

View full text Add to dashboard Cite

In this study, we investigated the potential of the multivariate curve resolution alternating least squares (MCR‐ALS) algorithm for analyzing three‐dimensional (3D) 1H‐MRSI data of the prostate in prostate cancer (PCa) patients. MCR‐ALS generates relative intensities of components representing spectral profiles derived from a large training set of patients, providing an interpretable model. Our objectives were to classify magnetic resonance (MR) spectra, differentiating tumor lesions from benign tissue, and to assess PCa aggressiveness. We included multicenter 3D 1H‐MRSI data from 106 PCa patients across eight centers. The patient cohort was divided into a training set (N = 63) and an independent test set (N = 43). Singular value decomposition determined that MR spectra were optimally represented by five components. The profiles of these components were extracted from the training set by MCR‐ALS and assigned to specific tissue types. Using these components, MCR‐ALS was applied to the test set for a quantitative analysis to discriminate tumor lesions from benign tissue and to assess tumor aggressiveness. Relative intensity maps of the components were reconstructed and compared with histopathology reports. The quantitative analysis demonstrated a significant separation between tumor and benign voxels (t‐test, p < 0.001). This result was achieved including voxels with low‐quality MR spectra. A receiver operating characteristic analysis of the relative intensity of the tumor component revealed that low‐ and high‐risk tumor lesions could be distinguished with an area under the curve of 0.88. Maps of this component properly identified the extent of tumor lesions. Our study demonstrated that MCR‐ALS analysis of 1H‐MRSI of the prostate can reliably identify tumor lesions and assess their aggressiveness. It handled multicenter data with minimal preprocessing and without using prior knowledge or quality control. These findings indicate that MCR‐ALS can serve as an automated tool to assess the presence, extent, and aggressiveness of tumor lesions in the prostate, enhancing diagnostic capabilities and treatment planning of PCa patients.

show abstract

MR-Derived Biomarkers for Cancer Characterization

Kim

Esmaeili

Moestue

et al. 2022

Biomarkers of the Tumor Microenvironment

View full text Add to dashboard Cite

Simultaneous 18F-fluciclovine Positron Emission Tomography and Magnetic Resonance Spectroscopic Imaging of Prostate Cancer

Cited by 5 publications

References 76 publications

18F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard

18F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard

A multivariate curve resolution analysis of multicenter proton spectroscopic imaging of the prostate for cancer localization and assessment of aggressiveness

MR-Derived Biomarkers for Cancer Characterization

Contact Info

Product

Resources

About